Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Management of metastatic cutaneous melanoma: updates in clinical practice.

Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC.

Ther Adv Med Oncol. 2019 May 22;11:1758835919851663. doi: 10.1177/1758835919851663. eCollection 2019. Review.

2.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

3.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH.

J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x.

4.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

5.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

6.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH.

Ann Surg Oncol. 2018 Feb;25(2):356-377. doi: 10.1245/s10434-017-6267-7. Epub 2017 Dec 13.

PMID:
29236202
7.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH.

J Clin Oncol. 2018 Feb 1;36(4):399-413. doi: 10.1200/JCO.2017.75.7724. Epub 2017 Dec 12.

PMID:
29232171
8.

Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.

Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, Agarwala SS, Venigalla ML, Chen Y, Zhen W, Mould DR, Holmlund JT, Brill JM, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):427-435. doi: 10.1016/j.ijrobp.2017.10.019. Epub 2017 Oct 16.

9.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

10.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

11.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

12.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

13.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

14.

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.

Andtbacka RH, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, Nemunaitis JJ, Harrington KJ, Chen L, Shilkrut M, Ross M, Kaufman HL.

Head Neck. 2016 Dec;38(12):1752-1758. doi: 10.1002/hed.24522. Epub 2016 Jul 13.

15.

Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

van Akkooi AC, Atkins MB, Agarwala SS, Lorigan P.

Am Soc Clin Oncol Educ Book. 2016;35:e505-14. doi: 10.14694/EDBK_159087. Review.

16.

The Role of Intralesional Therapies in Melanoma.

Agarwala SS.

Oncology (Williston Park). 2016 May;30(5):436-41. Review.

17.

Practical Approaches to Immunotherapy in the Clinic.

Agarwala SS.

Semin Oncol. 2015 Dec;42 Suppl 3:S20-7. doi: 10.1053/j.seminoncol.2015.10.001. Epub 2015 Oct 19. Review.

PMID:
26598056
18.

The Expanding Role of Immunotherapy in Melanoma--Introduction.

Agarwala SS.

Semin Oncol. 2015 Dec;42 Suppl 3:S1-2. doi: 10.1053/j.seminoncol.2015.10.004. Epub 2015 Oct 23. No abstract available.

PMID:
26598054
19.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

20.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM.

PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015.

21.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
22.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

PMID:
26014293
23.

Rose Bengal for melanoma treatment: will it translate to the clinic?

Agarwala SS.

Melanoma Manag. 2015 May;2(2):101-103. doi: 10.2217/mmt.15.8. Epub 2015 May 18. No abstract available.

24.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.

N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.

25.

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.

Ravaud A, Barrios CH, Alekseev B, Tay MH, Agarwala SS, Yalcin S, Lin CC, Roman L, Shkolnik M, Anak O, Gogov S, Pelov D, Louveau AL, Melichar B.

Ann Oncol. 2015 Jul;26(7):1378-84. doi: 10.1093/annonc/mdv170. Epub 2015 Apr 7.

PMID:
25851632
26.

Algorithm for the management of metastatic cutaneous melanoma.

Buzaid AC, Agarwala SS, Hauschild A, Atkins M.

Chin Clin Oncol. 2014 Sep;3(3):32. doi: 10.3978/j.issn.2304-3865.2014.07.01.

27.

Melanoma adjuvant therapy.

Thalanayar PM, Agarwala SS, Tarhini AA.

Chin Clin Oncol. 2014 Sep;3(3):26. doi: 10.3978/j.issn.2304-3865.2014.03.02.

28.

Systemic treatment of cutaneous and mucosal melanoma.

Agarwala SS, Guo J, Buzaid AC.

Chin Clin Oncol. 2014 Sep;3(3):25. doi: 10.3978/j.issn.2304-3865.2014.08.07. No abstract available.

29.

Intralesional therapy for advanced melanoma: promise and limitation.

Agarwala SS.

Curr Opin Oncol. 2015 Mar;27(2):151-6. doi: 10.1097/CCO.0000000000000158. Review.

30.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, Neuhaus SJ, Minor DR, Singer JM, Wachter EA.

Ann Surg Oncol. 2015 Jul;22(7):2135-42. doi: 10.1245/s10434-014-4169-5. Epub 2014 Oct 28.

31.

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.

Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade JL.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1241-52. doi: 10.1007/s00280-014-2460-6. Epub 2014 Apr 10.

PMID:
24718982
32.

Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.

Agarwala SS, Eggermont AM, O'Day S, Zager JS.

Cancer. 2014 Mar 15;120(6):781-9. doi: 10.1002/cncr.28480. Epub 2013 Dec 2. Review.

33.

Ipilimumab and its toxicities: a multidisciplinary approach.

Fecher LA, Agarwala SS, Hodi FS, Weber JS.

Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17. Review.

34.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R.

Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.

PMID:
23414587
35.

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

Agarwala SS.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1449-59. doi: 10.1586/era.12.120. Review.

PMID:
23249109
36.

Understanding and managing interferon-α-related fatigue in patients with melanoma.

Nashan D, Reuter K, Mohr P, Agarwala SS.

Melanoma Res. 2012 Dec;22(6):415-23. doi: 10.1097/CMR.0b013e328358d98c. Review.

PMID:
22968217
37.

Progression of cutaneous melanoma: implications for treatment.

Leong SP, Mihm MC Jr, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM.

Clin Exp Metastasis. 2012 Oct;29(7):775-96. doi: 10.1007/s10585-012-9521-1. Epub 2012 Aug 15. Review. Erratum in: Clin Exp Metastasis. 2012 Oct;29(7):797-9.

38.

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH; American Society of Clinical Oncology; Society of Surgical Oncology.

J Clin Oncol. 2012 Aug 10;30(23):2912-8. doi: 10.1200/JCO.2011.40.3519. Epub 2012 Jul 9. Review.

39.

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH; American Society of Clinical Oncology; Society of Surgical Oncology.

Ann Surg Oncol. 2012 Oct;19(11):3313-24. doi: 10.1245/s10434-012-2475-3. Epub 2012 Jul 6.

PMID:
22766987
40.

Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.

Chen CC, Hess GP, Liu Z, Gesme DH, Agarwala SS, Garay CC, Hill JW, Guo A.

Clin Genitourin Cancer. 2012 Dec;10(4):256-61. doi: 10.1016/j.clgc.2012.04.006. Epub 2012 Jun 7.

PMID:
22682982
41.

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group.

Eur J Cancer. 2011 Jul;47(10):1476-83. doi: 10.1016/j.ejca.2011.04.030. Epub 2011 May 18.

PMID:
21600759
42.

Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration.

Nicholson B, Agarwala SS.

J Opioid Manag. 2011 Jan-Feb;7(1):69-79. Review.

PMID:
21434586
43.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.

Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN Jr, Gandara DR.

Invest New Drugs. 2012 Apr;30(2):741-8. doi: 10.1007/s10637-010-9562-8. Epub 2010 Oct 22.

44.

Meeting report from the Third Global Workshop on Melanoma.

Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V.

Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-7. doi: 10.1111/j.1755-148X.2010.00738.x. Epub 2010 Aug 16. No abstract available.

PMID:
20718940
45.

Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.

Agarwala SS, O'Day SJ.

Cancer Treat Rev. 2011 Apr;37(2):133-42. doi: 10.1016/j.ctrv.2010.06.001. Epub 2010 Jul 16. Review.

PMID:
20638184
46.

Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.

Agarwala SS, Ribas A.

J Immunother. 2010 Jul-Aug;33(6):557-69. doi: 10.1097/CJI.0b013e3181dcd260. Review.

PMID:
20551840
47.

Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.

Agarwala SS, Case S.

Oncologist. 2010;15(3):236-45. doi: 10.1634/theoncologist.2009-0141. Epub 2010 Mar 9. Review.

48.

Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck.

Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Licato LL, Chada S, Gibbons RD, Olivier M, Hainaut P, Roth JA, Sobol RE, Goodwin WJ.

Clin Cancer Res. 2009 Dec 15;15(24):7719-7725.

49.
50.

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.

Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY.

Cancer. 2009 Nov 15;115(22):5228-36. doi: 10.1002/cncr.24576.

Supplemental Content

Loading ...
Support Center